Perception of oral contraception – do women think differently from gynaecologists?

References

• Lete I, Doval JL, Pérez-Campos E, et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception. 2008;77(4):276–282.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Westhoff CL, Bouchard C, et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021;104(3):222–228.
   PubMed Web of Science ®Google Scholar
• Skouby S. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care. 2004;9(2):57–68.
   PubMed Web of Science ®Google Scholar
• Næss IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699.
   PubMed Web of Science ®Google Scholar
• Hugon-Rodin J, Gompel A, Plu-Bureau G. MECHANISMS IN ENDOCRINOLOGY: epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171(6):R221–R230.
   PubMed Web of Science ®Google Scholar
• Bitzer J. Pharmacological profile of estrogens in oral contraception. Minerva Ginecol. 2011;63(3):299–304.
   PubMedGoogle Scholar
• FDA Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone [Internet]. Silver Spring (MD): US Food and Drug Administration. c2012 [cited 2015 Jul 17]. Available from: http: [http://www.fda.gov/Drugs/DrugSafety/%0Aucm299305.htm.
   Google Scholar
• Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception. 2011;84(1):19–34.
   PubMedGoogle Scholar
• Archer DF, Nakajima ST, Sawyer AT, et al. Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive. Obstet Gynecol. 2013;122(3):601–607.
   PubMedGoogle Scholar
• Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;(8):CD003989.
   PubMedGoogle Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3):577–582.
   PubMedGoogle Scholar
• Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24.
   PubMed Web of Science ®Google Scholar
• Kangasniemi MH, Haverinen A, Luiro K, et al. Estradiol valerate in COC has more favorable inflammatory profile than synthetic ethinyl estradiol: a randomized trial. J Clin Endocrinol Metab. 2020;105(7):e2483–e2490.
   Google Scholar
• Hagen AA, Barr M, Diczfalusy E. Metabolism OF 17-beta-oestradiol-4-14-C IN early infancy. Acta Endocrinol (Copenh). 1965;49:207–220.
   PubMedGoogle Scholar
• Gemzell‐Danielsson K, Apter D, Zatik J, et al. Estetrol‐drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022;29:63–71.
   Google Scholar
• Marshall C, Kandahari N, Raine-Bennett T. Exploring young women’s decisional needs for contraceptive method choice: a qualitative study. Contraception. 2018;97(3):243–248.
   PubMed Web of Science ®Google Scholar
• Lete I, Doval JL, Pérez-Campos E, et al. Factors affecting women’s selection of a combined hormonal contraceptive method: the TEAM-06 Spanish cross-sectional study. Contraception. 2007;76(2):77–83.
   PubMed Web of Science ®Google Scholar
• Costa ARR, Palma F, Sá JL, et al. Impact of a women’s counselling programme on combined hormonal contraception in Portugal – the IMAGINE study. Eur J Contracept Reprod Health Care. 2011;16(6):409–417.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Gemzell-Danielsson K, Roumen F, et al. The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care. 2012;17(1):65–78.
   PubMed Web of Science ®Google Scholar
• Zgliczynska M, Szymusik I, Sierocinska A, et al. Contraceptive behaviors in Polish women aged 18–35—a cross-sectional study. IJERPH. 2019;16(15):2723.
   Google Scholar
• Grossman D, Fernández L, Hopkins K, et al. Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas. Contraception. 2010;81(3):254–260.
   PubMed Web of Science ®Google Scholar
• Williamson LM, Parkes A, Wight D, et al. Limits to modern contraceptive use among young women in developing countries: a systematic review of qualitative research. Reprod Health. 2009;6(1):3.
   PubMedGoogle Scholar
• Águas F, Bombas T, Pereira da Silva D. Evaluation on portuguese women contraceptive practice. Acta Obs Ginecol Port. 2016;10(3):184–192.
   Google Scholar
• Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care. 2010;15(sup2):S42–S53.
   PubMed Web of Science ®Google Scholar
• Lee J, Tan T, Ang S. Female sexual dysfunction with combined oral contraceptive use. smedj. 2017;58(6):285–288.
   Google Scholar
• Boozalis A, Tutlam NT, Chrisman Robbins C, et al. Sexual desire and hormonal contraception. Obstet Gynecol. 2016;127(3):563–572.
   PubMed Web of Science ®Google Scholar
• Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013;18(1):27–43.
   PubMed Web of Science ®Google Scholar
• Wiebe ER, Brotto LA, MacKay J. Characteristics of women who experience mood and sexual side effects with use of hormonal contraception. J Obstet Gynaecol Canada. 2011;33(12):1234–1240.
   PubMedGoogle Scholar
• Schaffir J. Hormonal contraception and sexual desire: a critical review. J Sex Marital Ther. 2006;32(4):305–314.
   PubMed Web of Science ®Google Scholar
• Lindh I, Ellstrom AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011;26(7):1917–1924.
   PubMedGoogle Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;(1):CD003987.
   PubMedGoogle Scholar
• Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care. 2016;21(5):347–355.
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am. J. Obstet. Gynecol. 2017;216(6):580.e1–580.e9.
   PubMed Web of Science ®Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. In: Arowojolu AO, editor. Cochrane database of systematic Review. Chichester (UK): John Wiley & Sons, Ltd.; 2012.
   Google Scholar
• Słopień R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. PM. 2018;17(1):1–4.
   Google Scholar
• Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86(6):606–621.
   PubMed Web of Science ®Google Scholar
• Egarter C, Frey Tirri B, Bitzer J, et al. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health. 2013;13(1):9.
   PubMedGoogle Scholar
• Kestemont P, Creinin MD, Nfon E, et al. P51 The potential environment impact of estetrol, a native estrogen in development for oral contraception. Contraception. 2020;102(4):293.
   Web of Science ®Google Scholar